Spondylolisthesis Surgery: What the Fusion Adds and What It Costs

For many patients with a degenerative slip, adding a fusion to spondylolisthesis surgery buys little. In Norway, decompression alone was non-inferior (no worse). In Sweden, repeat-surgery rates were nearly the same with or without fusion. A retired bookkeeper weighing that operation brought a folder. It held every bill her back had run up in four years.

A retired bookkeeper had a slipped vertebra at the fourth lumbar level. She came in with two things. One was a surgeon’s proposal for spondylolisthesis surgery, a decompression and fusion. The other was a folder holding every bill her back had run up in four years. She wanted to know which line had been the costly one. The honest answer was the smallest: a bottle of ibuprofen. That is because it started a chain of care in which nobody asked what was wrong.

The video above, The Four-Dollar Bottle Costs the Years, is Chapter 18 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. Are you weighing spondylolisthesis surgery for a degenerative slip? Below is how the value of an operation is measured. Then comes what the trials found when they tested the fusion itself. Last is what should come before a date is booked. Every dollar figure below is a published research estimate, never a quote for any service.

How value is counted: the quality-adjusted life year

Health economists measure value in quality-adjusted life years. A year in perfect health counts as one. A year lived at half of perfect health counts as a half. A treatment is judged by what it costs to buy one full year of health. The old American benchmark was 50,000 dollars. Even the economists who used it called it a mystery. By 2020, 47.0 percent of American cost studies used 100,000 dollars. One model looked at what new spending costs in lost coverage and lost lives. It put the true threshold near 104,000.

Chronic pain shrinks the very year being counted. A Danish national catalog used a scale where perfect health is 1. Back pain scored 0.619. Fibromyalgia scored 0.490, below dementia at 0.546. In a Singapore registry of patients booked for degenerative lumbar spine surgery, the average was 0.43. That is why a treatment that restores function is worth so much. And a treatment that fails is costly at any price.

The surgeon’s case, with its best numbers

The Spine Patient Outcomes Research Trial, known as SPORT, is the largest trial of spine surgery ever run. Its numbers make the strongest case for operating. For degenerative spondylolisthesis, surgery cost 115,600 dollars per year of health at two years. That improved to 64,300 at four, because the costs came up front while the benefit kept adding up. At eight years, the spondylolisthesis patients who had the operation still did better on every primary outcome. I have referred patients for exactly those operations.

What adding a fusion buys in spondylolisthesis surgery

The real choice inside most proposals is not surgery versus no surgery. It is decompression alone versus decompression plus fusion. The trials that tested that head to head are sobering. In Sweden, 247 patients with stenosis were randomized, 135 of them with a slipped vertebra. Disability scores at two years were 27 and 24. Hospital stays ran 7.4 days with fusion against 4.1 without. Over about six and a half years, 22 percent of the fused and 21 percent of the unfused had more lumbar surgery. In Norway, decompression alone was non-inferior for spondylolisthesis. With it, 71.4 percent reached a meaningful improvement, against 72.9 percent with fusion.

The American trial that favored fusion found a 5.7-point edge in physical function. Its confidence interval nearly touched zero. Repeat surgery ran 14 percent with fusion against 34 percent without. The price was more blood loss and longer stays. Run through a cost model, adding the fusion cost 2,416,281 dollars per year of health over decompression alone. Not one sensitivity scenario, zero percent, made it cost-effective. In the two-year SPORT data, fusion over laminectomy alone for spondylolisthesis came to 997,400 dollars per year of health.

The years after the estimate

Look at 725 injured workers who had a lumbar fusion. Two years later, 26 percent were back at work. Among matched patients who had no operation, 67 percent were. Of the fused workers, 27 percent had a second operation, and 76 percent were still taking opioids. In a Korean nationwide sample, 18.4 percent had another operation within ten years of a first stenosis operation. A surgical estimate prices a day. The patient lives the decade. Pain that outlasts a good operation is covered in why a leg can still burn after back surgery that worked.

The bridge, and the caveat that comes with it

Injections sit between the first pill and the operation. Cost studies from interventional trials put a lumbar interlaminar epidural at 1,976.58 dollars per year of health in direct cost. That is about one-thirtieth of the surgical figures. Those studies come from single centers. The procedures’ own backers wrote them, with no surgical comparison arm, and every paper admits it. The independent record is thinner. In a British randomized trial of sciatica, microdiscectomy was no better than a transforaminal injection at eighteen weeks. And 59 percent of the injection group never needed the operation.

An epidural calms an inflamed nerve root. It does so long enough for a person to walk, sleep and load the spine again, as described in what an epidural steroid injection actually does. The injection is not the treatment. It opens the window in which the treatment happens.

The cheap first move and the blood test nobody ordered

First moves set the order of what follows. Take 373,717 veterans with low back pain. Starting with an opioid instead of physical therapy was tied to 1.69 times the odds of spine surgery within a year. It was tied to 17.8 times the odds of chronic opioid use. Among injured workers, more than seven days of opioids in the first six weeks doubled the odds of disability a year later. The anti-inflammatory used instead of the opioid has its own bill. The odds of a heart attack rise 1.48-fold in the first week of ibuprofen. Early imaging in 5,239 older adults added cost without improving disability at a year, for reasons explained in why most MRI findings show up in people without pain.

Her folder had no line for a hemoglobin A1c because nobody had ordered one. It was 6.4. One in four American health-care dollars is spent on someone with diabetes. Take the government’s own 2026 fee schedules. A fasting insulin, A1c, C-reactive protein and lipid panel together are paid about one-fifth of what a lumbar MRI is. Meanwhile insulin resistance shows up years before diabetes and a glucose test alone can miss it.

Least destructive first, with the exceptions named

Treating the terrain is cheap by the same yardstick. The lifestyle arm of the Diabetes Prevention Program cost 10,037 dollars per year of health over ten years. It cut new diabetes by 34 percent. For a slipped vertebra, walking and cutting sugar and industrial seed oils matter for a body-level reason. They bring insulin down. Lower insulin quiets the metabolic inflammation that sensitizes the nerves around a narrowed canal.

The exceptions are real. Cauda equina syndrome (pinched nerves at the base of the spine), with new bladder or bowel change, is decompressed within 48 hours. That roughly doubles the odds of bladder recovery. A herniated disc that has failed everything is good surgical value at four years. Those patients go to the surgeon the same week. She was not one of them. She had a positive diagnostic block. Then two transforaminal injections each gave her about ten weeks. In those weeks she went from four hundred yards of walking to a mile, while her insulin came down. She kept the option of surgery. Her next question was how to know which physician to trust. That is taken up in what doctor reviews measure and what they miss, and the metric that governed opioid care is examined in why a dose is not a diagnosis. The limits of each figure are spelled out in the Chapter 18 Deep Dive.

Frequently asked questions

What is the success rate of lumbar fusion?

It depends on who is operated on and what counts as success. In SPORT, spondylolisthesis patients who had surgery kept an edge at eight years. Yet among 725 injured workers who had a fusion, only 26 percent were working two years later. And 76 percent were still on opioids. The pain generator and the reason for the fusion matter more than the average. Walking tolerance is often the clearest sign of how stenosis is behaving, as described in leg pain when you walk that eases when you lean forward.

Is decompression without fusion enough for spondylolisthesis?

For many patients the trials suggest it can be. In Norway, decompression alone was non-inferior to fusion for degenerative spondylolisthesis. In Sweden, repeat-surgery rates were nearly the same with or without fusion. One American trial found fewer reoperations with fusion, 14 against 34 percent. Ask your surgeon what the fusion itself is expected to add for your particular slip. Movement is part of any plan either way, explained in whether walking is good for spinal stenosis.

What is a quality-adjusted life year?

A quality-adjusted life year combines how long and how well a person lives. One year in perfect health equals one. A year at half of perfect health equals a half. Economists divide the cost of a treatment by the years of health it adds. Then they compare the result with a benchmark. Most American cost studies now set it at 100,000 dollars. Early conservative care has been studied the same way, as covered in early physical therapy for low back pain and healthcare cost.

Can an epidural injection delay back surgery?

For some people it does. Pooled randomized trials suggest that between one-third and half of surgical candidates who get an epidural avoid the operation. Still, one in four patients given an epidural for herniation or stenosis goes on to surgery within five years. The number of injections should follow clinical need, not a fixed series. Each should come with a plan for the weeks it buys. Spacing questions are answered in how often you can have a steroid injection.

Is ibuprofen a safe long-term answer for back pain?

It carries costs that do not show up on the receipt. The odds of a heart attack rose 1.48-fold in the first week of ibuprofen. Adding an anti-inflammatory to a blood-pressure regimen doubled the rate of acute kidney injury. Anyone using one regularly should review it with their physician rather than change it on their own. Its effects on the digestive tract are covered in the stomach damage long-term NSAID use can cause.

Sources

1. Tosteson, A. N., Lurie, J. D., Tosteson, T. D., Skinner, J. S., Herkowitz, H., Albert, T., Boden, S. D., Bridwell, K., Longley, M., Andersson, G. B., Blood, E. A., Grove, M. R., Weinstein, J. N., & SPORT Investigators (2008). Surgical treatment of spinal stenosis with and without degenerative spondylolisthesis: cost-effectiveness after 2 years. Annals of Internal Medicine, 149(12), 845–853. https://doi.org/10.7326/0003-4819-149-12-200812160-00003
2. Tosteson, A. N. A., Tosteson, T. D., Lurie, J. D., Abdu, W., Herkowitz, H., Andersson, G., Albert, T., Bridwell, K., Zhao, W., Grove, M. R., Weinstein, M. C., & Weinstein, J. N. (2011). Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine, 36(24), 2061–2068. https://doi.org/10.1097/BRS.0b013e318235457b
3. Försth, P., Ólafsson, G., Carlsson, T., Frost, A., Borgström, F., Fritzell, P., Öhagen, P., Michaëlsson, K., & Sandén, B. (2016). A Randomized, Controlled Trial of Fusion Surgery for Lumbar Spinal Stenosis. The New England Journal of Medicine, 374(15), 1413–1423. https://doi.org/10.1056/NEJMoa1513721
4. Austevoll, I. M., Hermansen, E., Fagerland, M. W., Storheim, K., Brox, J. I., Solberg, T., Rekeland, F., Franssen, E., Weber, C., Brisby, H., Grundnes, O., Algaard, K. R. H., Böker, T., Banitalebi, H., Indrekvam, K., & Hellum, C. (2021). Decompression with or without Fusion in Degenerative Lumbar Spondylolisthesis. The New England Journal of Medicine, 385(6), 526–538. https://doi.org/10.1056/NEJMoa2100990
5. Ghogawala, Z., Dziura, J., Butler, W. E., Dai, F., Terrin, N., Magge, S. N., Coumans, J. V., Harrington, J. F., Amin-Hanjani, S., Schwartz, J. S., Sonntag, V. K., Barker, F. G., & Benzel, E. C. (2016). Laminectomy plus Fusion versus Laminectomy Alone for Lumbar Spondylolisthesis. The New England Journal of Medicine, 374(15), 1424–1434. https://doi.org/10.1056/NEJMoa1508788
6. Sastry, R. A., Levy, J. F., Chen, J. S., Weil, R. J., Oyelese, A. A., Fridley, J. S., & Gokaslan, Z. L. (2024). Lumbar Decompression With and Without Fusion for Lumbar Stenosis With Spondylolisthesis: A Cost Utility Analysis. Spine, 49(12), 847–856. https://doi.org/10.1097/BRS.0000000000004928
7. Nguyen, T. H., Randolph, D. C., Talmage, J., Succop, P., & Travis, R. (2011). Long-term outcomes of lumbar fusion among workers’ compensation subjects: a historical cohort study. Spine, 36(4), 320–331. https://doi.org/10.1097/BRS.0b013e3181ccc220
8. Wilby, M. J., Best, A., Wood, E., Burnside, G., Bedson, E., Short, H., Wheatley, D., Hill-McManus, D., Sharma, M., Clark, S., Baranidharan, G., Price, C., Mannion, R., Hutchinson, P. J., Hughes, D. A., Marson, A., & Williamson, P. R. (2021). Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica secondary to herniated lumbar disc (NERVES): a phase 3, multicentre, open-label, randomised controlled trial and economic evaluation. The Lancet Rheumatology, 3(5), e347–e356. https://doi.org/10.1016/S2665-9913(21)00036-9
9. Schmidt, C., Borgia, M., Zhang, T., Gochyyev, P., Shireman, T. I., & Resnik, L. (2023). Initial treatment approaches and healthcare utilization among veterans with low back pain: a propensity score analysis. BMC Health Serv Res, 23(1), 275. https://doi.org/10.1186/s12913-023-09207-y
10. Diabetes Prevention Program Research Group (2012). The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care, 35(4), 723–30. https://doi.org/10.2337/dc11-1468

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 18 of The Pained Brain by Dr. Padda and Dr. KrisJay Fucanan, MD. Last reviewed September 2026.

Dr. Gurpreet Singh Padda, MD, MBA, MHP